Loading…
Pharmaceutical company developing new antibiotics for drug-resistant infections alongside generic formulation manufacturing.
Pharmaceutical company developing new antibiotics for drug-resistant infections alongside generic formulation manufacturing.
Has earned mainly from selling established generic drugs in the UK, Ireland, the US and emerging markets, since it sold its Indian branded-drugs business to Dr. Reddy's in 2020. The antibiotic programme is the research bet on top of that. The Khorakiwala family, who founded the company, remain its controlling shareholders.
In one line: A small, antibiotic-focused pharma innovator.
Moat: narrow (IP / patents). One of few companies globally developing new antibiotic classes, though commercialization risk remains high.
Headquarters: Mumbai, India · Founded: 1960 · Employees: 4,084
Size Wockhardt (WOCKPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $3.35B, the 267th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,947 on 6 Nov 2026.
Performance Over six months the shares gained 18.9%, against +2.0% for the median peer and 0.0% for the India market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 25.7% over the last twelve months (peer median +13.3%); the operating margin is 13.1% (peer median 18.9%).
Valuation It trades at 8.9× enterprise value to sales against a peer median of 3.6× (5th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 57% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +53 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 11.3 points below its cost of capital (16.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹37.5B | ₹33.2B | ₹29.1B | ₹27.9B | ₹26.5B |
| Revenue growth | — | +14% | +5% | +5% | — |
| Gross profit | ₹14.6B | ₹9.63B | ₹6.81B | ₹5.64B | ₹4.56B |
| EBITDA | ₹7.21B | ₹5.74B | ₹3.00B | ₹1.47B | ₹790M |
| Net income | ₹4.10B | ₹2.13B | -₹470M | -₹4.63B | -₹5.59B |
| Free cash flow | n/a | ₹640M | -₹2.48B | -₹340M | ₹1.11B |
| Capital expenditure | n/a | ₹3.64B | ₹3.65B | ₹2.16B | ₹2.09B |
| Total debt | ₹22.4B | ₹22.3B | ₹20.2B | ₹23.6B | ₹21.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Wockhardt WOCKPHARMA.NS | $3.35B | +19% | +26% | 13% | 8.9× | 56.9% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $47.3B | +1% | +12% | 23% | 6.8× | 28.4% |
| Cipla CIPLA.NS | $12.1B | +4% | -1% | 13% | 3.8× | 28.2% |
| Aurobindo Pharma AUROPHARMA.NS | $10.9B | +22% | +14% | 15% | 2.8× | 21.0% |
| Lupin LUPIN.NS | $9.65B | -19% | +24% | 24% | 2.9× | 8.8% |
| Dr. Reddy's Laboratories DRREDDY.NS | $12.1B | +5% | -4% | 9% | 3.5× | 30.1% |
| Basilea Pharmaceutica BSLN.SW | $1.07B | +27% | +5% | 24% | 3.2× | -5.7% |
| Shionogi & 4507.T | $16.6B | -6% | +46% | 29% | 4.6× | -0.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | WOCKPHARMA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.5% | +3.5% | 3rd lowest of 21 |
| 6-month return | +18.9% | +2.0% | 6th highest of 20 |
| Distance from 52-week high | -19.6% | -24.0% | 10th highest of 21 |
| Revenue growth (TTM) | +25.7% | +13.3% | 9th highest of 19 |
| Operating margin | 13.1% | 18.9% | 8th lowest of 18 |
| EV / Sales | 8.9× | 3.6× | 5th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 56.9% | 0.4% | most demanding of 15 |
| Growth delivered (Del g) | +4.2% | +8.8% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | +52.7 pp | -11.5 pp | most demanding of 15 |
| ROIC minus cost of capital | -11.3 pp | +8.7 pp | 2nd lowest of 15 |
| EV / EBITDA | 46.5× | 24.3× | 3rd most expensive of 9 |
| Net debt / EBITDA | 2.2× | -0.7× | 4th most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Wockhardt WOCKPHARMA.NS | India | $3.35B | +19% | +26% | 13% | 8.9× | 56.9% | +4.2% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 3.8× | n/a | n/a |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | 4.6× | 31.9% | +159.5% |
| China National Medicines 600511.SS | China | $3.31B | +2% | +3% | 4% | 0.3× | -9.8% | +5.4% |
| China Medical System 0867.HK | Hong Kong | $3.30B | -16% | +15% | 20% | 2.1× | 2.9% | +2.7% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 3.7× | 15.2% | +61.4% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.28B | +39% | +45% | 36% | 19.3× | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 3.1× | -2.2% | +12.0% |
| Viridian Therapeutics VRDN | United States | $3.23B | +72% | -63% | -1,781% | 99.3× | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.21B | +21% | +76% | 7% | 6.7× | 48.9% | +367.3% |
| Tasly Pharmaceutical 600535.SS | China | $3.20B | -5% | -4% | 19% | 2.3× | -7.6% | -9.6% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $3.18B | -7% | -11% | 24% | 3.6× | -2.2% | +7.0% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 12.8× | 20.5% | +98.4% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 2.7× | -2.8% | +10.6% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 1.8× | -4.5% | -1.0% |
| Hybio Pharmaceutical 300199.SZ | China | $3.08B | +16% | +70% | 31% | 14.7× | 40.1% | +6.1% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 2.4× | 16.7% | +19.4% |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.69B | -11% | -10% | 19% | 2.3× | -7.7% | +2.0% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |